and the slow post-patent decline of epilepsy drug Keppra. UCB now has three core brands: Cimzia, for Crohn's disease and rheumatoid arthritis (RA), epilepsy treatment Vimpat and Neupro for ...
In a report released today, Charles Pitman CFA from Barclays reiterated a Buy rating on UCB SA (0NZT – Research Report), with a price target of ...
Shares in UCB slid this morning after the Belgian company announced its refractory epilepsy drug candidate padsevonil had failed a phase 2b trial. The ARISE trial of padsevonil did not reach ...
ATLANTA, Dec. 6, 2024 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced data being presented at the American Epilepsy Society (AES) Annual Meeting, taking place December 6 ...
Hosted on MSN14d
She got seizures at 10 months old. So her dad wrote a musical about epilepsy and empathyNews of the stage show reached UCB, a Belgium-based pharmaceutical company that produces various medications that treat epilepsy. UCB had recently contributed funding to "Under the Lights," Miles ...
Hosted on MSN2mon
CBC acquires UCB’s neurology and allergy business in ChinaThe deal encompasses UCB's Zhuhai manufacturing site and its brands Xyzal, Keppra, Zyrtec, Vimpat and Neupro. They are set to be the cornerstone assets for CBC as it develops an integrated central ...
Enroll pregnant patients exposed to levetiracetam in the North American Antiepileptic Drug pregnancy registry (888) 233-2334 or the UCB AED Pregnancy Registry (888) 537-7734.
Enroll pregnant patients exposed to levetiracetam in the North American Antiepileptic Drug pregnancy registry (888) 233-2334 or the UCB AED Pregnancy Registry (888) 537-7734.
UCB SA (OTCMKTS:UCBJY – Get Free Report)’s stock price passed below its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $96.49 and traded as low as $93.22.
UCB SA (0NZT) Company Description ... Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, both of which have lost patent protection. The firm’s key products ...
Results of a social media listening study of women of childbearing age with epilepsy underscore the need for HCPs to provide relevant information at critical time ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback